一种用于食管和贲门光动力治疗的新型远程经内镜球囊施药器。
A new long-range through-the-scope balloon applicator for photodynamic therapy in the esophagus and cardia.
作者信息
Gossner L, May A, Sroka R, Ell C
机构信息
Dept. of Medicine II, Klinikum der Landeshauptstadt Wiesbaden, Germany.
出版信息
Endoscopy. 1999 Jun;31(5):370-6. doi: 10.1055/s-1999-31.
BACKGROUND AND STUDY AIMS
Photodynamic therapy (PDT) is a new local, endoscopically controlled therapeutic technique based on the sensitization of malignant and precancerous lesions prior to light-induced tissue destruction. PDT of Barrett's esophagus with severe dysplasia, or of mucosal carcinomas and superficial squamous-cell cancer of the esophagus, requires light application devices allowing homogeneous illumination of the tissue surface in spite of esophageal motility and respiratory movement. On the basis of a commercially available through-the-scope balloon system, we developed a long-range light applicator for homogeneous and circumferential irradiation during PDT, and describe here the initial clinical experience with the device.
PATIENTS AND METHODS
The new balloon applicator consists of a flexible cylindrical diffuser fiber with a length of up to 10 cm, depending on the lesion to be illuminated, and an inflatable balloon based on the type of balloon used for esophageal dilation. The balloon is made of a transparent polyurethane membrane with negligible absorption (<5%) at lambda = 600-700 nm, and it can be positioned through the biopsy channel of a conventional endoscope, with direct endoscopic visualization of the targeted lesion. The light intensity distribution perpendicular to the optical axes of the diffuser was measured for red laser light (lambda = 632.8 nm) and for green laser light (lambda = 542 nm). The study of photodynamic treatment included two women and four men (aged 48-79 years) with histologically proved high-grade dysplasia (n = 2) or mucosal cancer in Barrett's esophagus (n = 2) and superficial squamous-cell cancer (SCC) (n = 2), who had undergone EUS staging showing uT0 or uT1N0. Laser light irradiation was conducted after oral ingestion of 5-aminolevulinic acid (5-ALA) or intravenous administration of meta-(tetrahydroxyphenyl)chlorin (mTHPC).
RESULTS
Both in vitro and in vivo, precise positioning of the new application system at the targeted tissue and homogeneous illumination were feasible, safe and effective. The total efficiency of transmitted light at wavelengths of lambda = 632.8 nm and lambda = 542 nm was 85-90%. A high degree of homogeneity was measured with applicator lengths of between 15 mm and 95 mm, and the maximum deviation from the mean intensity extended over a range of 40% over the total length of 80 mm. High-grade dysplasia was eradicated in all patients, and in addition mucosal cancer was successfully destroyed in three-quarters of them, requiring an average of 1.3 treatment sessions, with a mean follow-up of 12 months (range 10-15 months).
CONCLUSIONS
This centering balloon system may in the future be capable of improving light application techniques during esophageal photodynamic therapy, making PDT a more reliable alternative modality for minimally invasive treatment of high-grade dysplasia and early Barrett's esophagus or squamous-cell carcinoma, as compared with esophagectomy.
背景与研究目的
光动力疗法(PDT)是一种新的局部、内镜控制的治疗技术,基于在光诱导组织破坏之前对恶性和癌前病变进行敏化处理。对伴有严重异型增生的巴雷特食管、食管黏膜癌或浅表鳞状细胞癌进行光动力疗法,需要光应用设备,即使在食管蠕动和呼吸运动的情况下,也能使组织表面均匀受照。基于一种市售的经内镜球囊系统,我们开发了一种用于光动力疗法期间进行均匀圆周照射的远程光 applicator,并在此描述该设备的初步临床经验。
患者与方法
新型球囊 applicator 由一根长度可达 10 cm 的柔性圆柱形扩散光纤组成,其长度取决于要照射的病变,以及一个基于用于食管扩张的球囊类型的可充气球囊。该球囊由透明聚氨酯膜制成,在波长λ = 600 - 700 nm 时吸收可忽略不计(<5%),并且可以通过传统内镜的活检通道定位,直接在内镜下观察目标病变。测量了垂直于扩散器光轴的红色激光(λ = 632.8 nm)和绿色激光(λ = 542 nm)的光强分布。光动力治疗研究纳入了两名女性和四名男性(年龄 48 - 79 岁),他们经组织学证实为高级别异型增生(n = 2)、巴雷特食管黏膜癌(n = 2)或浅表鳞状细胞癌(SCC)(n = 2),且已接受 EUS 分期显示为 uT0 或 uT1N0。在口服 5 - 氨基乙酰丙酸(5 - ALA)或静脉注射间 -(四羟基苯基)氯啉(mTHPC)后进行激光照射。
结果
在体外和体内,新应用系统在目标组织的精确定位和均匀照射都是可行、安全且有效的。在波长λ = 632.8 nm 和λ = 542 nm 时,透射光的总效率为 85 - 90%。当 applicator 长度在 15 mm 至 95 mm 之间时,测量到高度均匀性,在 80 mm 的总长度上,与平均强度的最大偏差范围为 40%。所有患者的高级别异型增生均被根除,此外,四分之三的患者黏膜癌被成功破坏,平均需要 1.3 个治疗疗程,平均随访 12 个月(范围 10 - 15 个月)。
结论
这种中心球囊系统未来可能能够改善食管光动力疗法期间的光应用技术,与食管切除术相比,使光动力疗法成为一种更可靠的替代方式,用于微创治疗高级别异型增生以及早期巴雷特食管或鳞状细胞癌。